The nature of crosspriming immunogens for CD8 + T cell responses is highly controversial. By using a panel of T cell receptor-like antibodies specific for viral peptides bound to mouse D b major histocompatibility complex class I molecules, we show that an exceptional peptide (PA 224-233 ) expressed as a viral minigene product formed a sizeable cytosolic pool continuously presented for hours after protein synthesis was inhibited. PA 224-233 pool formation required active cytosolic heat-shock protein 90 but not ER g96 and uniquely enabled crosspriming by this peptide. These findings demonstrate that exceptional class I binding oligopeptides that escape proteolytic degradation are potent crosspriming agents. Thus, the feeble immunogenicity of natural proteasome products in crosspriming can be attributed to their evanescence in donor cells and not an absolute inability of cytosolic oligopeptides to be transferred to and presented by professional antigen-presenting cells.
INTRODUCTION
Direct antigen presentation is based on proteasome-initiated degradation of defective ribosomal products (DRiPs) and other rapidly degraded endogenous translation products (Eisenlohr et al., 2007; Yewdell, 2007) . Typically, peptides of eight or more residues are transported by the transporter associated with antigen processing (TAP) into the endoplasmic reticulum (ER) where final trimming of COOH-terminal residues is mediated by ER-associated aminopeptidase (ERAAP). Peptide binding releases nascent class I molecules from the loading complex, initiating their transport to the plasma membrane for recognition by CD8 + T cells.
In viral infections, direct presentation enables CD8 + T cell activation by virus-infected cells, including dendritic cells (DCs), which can initiate naive CD8
+ T cell response in lymph nodes and spleen. But what if viruses cannot (or will not) express their proteins in DCs? In this case, an alterative pathway exists, termed crosspriming, where DCs process antigens acquired from infected cells and present them to naive CD8 + T cells (Shen and Rock, 2006) . Controversy swirls around virtually every aspect of crosspriming. A substantial literature has grown around the concept that crosspriming is mediated by DC acquisition of glucoseregulated protein 94 (GRP94) (also known as glycoprotein 96 [gp96] ) and other chaperones bearing oligopeptides derived from proteasomal antigen degradation (Srivastava, 2002) . It has proven difficult, however, for many laboratories to recover peptides bound to gp96 purified from antigen-presenting cells, or even to demonstrate that gp96 binds to oligopeptides with an affinity consistent with its proposed role in crosspriming (Demine and Walden, 2005; Javid et al., 2007; Nicchitta et al., 2004; Wallin et al., 2002; Ying and Flatmark, 2006) . Purified gp96 and a variety of other chaperones demonstrate antigenspecific crosspriming activity, but this activity is weak, and the adjuvant role of contaminants (e.g., lectins, bacterial lipopolysaccharide) in the phenomenon is a concern. Heat-shock protein 90 (HSP90) has been recovered from cells bound to truncated forms of a model antigen (Kunisawa and Shastri, 2006) , but the crosspriming activity of such complexes has not been demonstrated in the context of intact cells as immunogens. Moreover, seven laboratories recently published studies pointing to proteasome substrates rather than proteasome products as the source of crosspriming antigens (Basta et al., 2005; Donohue et al., 2006; Freigang et al., 2007; Gasteiger et al., 2007; Norbury et al., 2004; Shen and Rock, 2004; Wolkers et al., 2004) . This conclusion jibes with the original observation by Rammensee and colleagues that antigenic oligopeptides are recovered only from cells expressing class I molecules capable of presenting the peptides (Falk et al., 1990) . Further, the finding that cytosolic oligopeptides are rapidly destroyed by endopeptidases and aminopeptidases (half-life on the order of 10 s) (Reits et al., 2004) is inconsistent with the hypothesis that oligopeptides exist in stable complexes with molecular chaperones.
A key advance in the antigen presentation field was the introduction of antibodies with TCR-like specificities, generated by standard hybridoma technology or by screening of antibody phage display libraries (Andersen et al., 1996; Denkberg and Reiter, 2006; Porgador et al., 1997) . Such reagents enable measurement of cell-surface major histocompatibility complex (MHC) class I peptide complexes with great precision by flow cytometry. Here we describe the generation and characterization of a panel of TCR-like phage-displayed antibodies specific for well-defined influenza A virus (IAV) peptides bound to H-2D b molecules. We then use these phage antibodies to study the cell biology and immunology of oligopeptides introduced into the cytosol and ER of antigen-presenting cell and crosspriming donor cells as biosynthesized minigene products. These determinants top the defined anti-IAV immunodominance hierarchy in B6 mice. Out of numerous candidates identified, we chose the Fabs that demonstrated the best signal-to-noise ratio and sensitivity. As seen in Figure S1 available online, the three Fabs chosen selectively recognized both purified D b and cellsurface D b complexed with their cognate determinants. The threshold for peptide recognition on peptide-pulsed EL4 cells with low-temperature-induced peptide-receptive D b molecules occurred at $10 À9 M. This is similar to the sensitivity of the 25-D1.16 mAb, which is specific for K b -SIINFEKL complexes. This reagent represents ''gold standard'' for highly sensitive and specific TCR-like antibody recognition (Porgador et al., 1997) .
RESULTS

Isolation of Human
We next tested the ability of the TCR-like Fabs (Fab TCR s) to bind to endogenous complexes generated from cytosolic or ER-targeted minigene products expressed by recombinant vaccinia viruses (rVVs) (see schematic of rVVs in Figure S2 ). Minigene products are typically expressed at very high copy numbers (tens of thousands per cell) relative to peptides generated from full-length proteins (ten to a few thousand copies per cell) (Princiotta et al., 2003) . Each of the six minigene products tested was easily detected by its cognate Fab TCR (Figure 1 ). Addition of a signal sequence increased the numbers of cell-surface complexes very slightly for PB1-F2 62-70 and $5-fold for NP [366] [367] [368] [369] [370] [371] [372] [373] [374] and PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] .
To determine the TAP dependence of complex formation, we infected human T2-D b cells with the rVVs (T2 cells are EBV-transformed lymphoblasts that lack both TAP1 and TAP2 genes, and were repeated more than six times. T2-D b infections were repeated two times.
consequently, cytosolic peptides have limited access to the ER). This revealed that, as expected, each of the cytosolic minigene products demonstrated only slight TAP-independent presentation, whereas ER targeting bypassed the requirement for TAP for PB1-F2 62-70 and PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] . Surprisingly, presentation of ERtargeted NP 366-374 remained largely TAP dependent. A possible explanation is the presence of Ala as the NH 2 -terminal residue in NP [366] [367] [368] [369] [370] [371] [372] [373] [374] , because Ala is a preferred residue at the P1 site of signal peptidase cleavage, which may therefore destroy the peptide when it is translocated via the translocon. If this is the case, the enhanced ability of ES-NP [366] [367] [368] [369] [370] [371] [372] [373] [374] 
would presumably be due to the ability of the leader sequence to enhance TAP-mediated antigen presentation. This could be due to resistance to degradation by cytosolic or ER proteases or enhanced TAP-mediated transport into the ER of the full-length ES peptide or, more likely, a NH 2 -terminally trimmed version. These findings demonstrate that Fab TCR s can be used as highly specific reagents to precisely quantitate cell-surface D b -peptide complexes generated from VV-encoded minigenes.
Kinetics of Cell-Surface Complex Presentation via TCR-like Fabs
We next examined the kinetics of cell-surface complex expression at 30 min intervals after infection of L-D b cells with rVVs expressing the three determinants. In each case, cognate peptide-MHC complexes were first detected by the Fab TCR s 60-90 min after infection and quickly reached V max of complex generation (i.e., the maximal increase in the rate of complex accumulation). This behavior is similar to expression of K b -Ova 257-264 complexes (Princiotta et al., 2003) and is exactly what is expected for peptides that rapidly achieve saturating amounts of expression for feeding the class I pathway and require little or no processing for binding to class I molecules. Addition of BFA, which blocks MHC egress from the secretory pathway by inducing Golgi complex disassembly and redistribution of Golgi complex proteins into the ER (Yewdell and Bennink, 1989) , resulted in an immediate block of cell-surface complex accretion. In the case of ES-PB1-F2 62-70 , BFA caused a steep and steady decline in surface complexes, indicative of a relatively low complex stability (t 1/2 of $120 min). Under the same conditions, both ER-targeted and cytosolic NP 366-374 demonstrated intermediate complex stability whereas both cytosolic and ERtargeted PA 224-233 generated highly stable complexes. This hierarchy of complex stability agrees with the stability of complexes generated with synthetic peptides that we previously reported ( Figure 3 in Chen et al. [2004] ), findings that we repeated by using the Fab TCR s (data not shown).
Cellular oligopeptides are believed to be nearly completely degraded in a few seconds (Reits et al., 2004) , so the kinetic difference between blocking protein synthesis and blocking surface delivery with BFA should be minimal and difficult to detect when sampling cells at 30 min intervals. This was indeed the case for NP [366] [367] [368] [369] [370] [371] [372] [373] [374] (Figures 2A and 2D) . A trivial explanation for this finding is that the translation of PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] complexes that feeds the class I pathway for hours after protein synthesis shutdown.
The kinetics of pool formation is most consistent with the former possibility. When we blocked protein synthesis at increasing times after infection, the size of the pool increased with time of expression. In the interval between 150 and 180 min, the pool increased from 70 flow units to 105 units ( Figure 2G ). Notably, this is twice the amount of complexes delivered to the cell surface over the identical interval. Because the V max of cell-surface complex delivery has been reached by 150 min, the large increase in the size of the pool over the next 30 min is difficult to reconcile with a pool of D b -PA 224-233 complexes in the secretory pathway if the size of this pool is directly related to the rate of ER export and cell-surface complex delivery. These experiments demonstrate that PB1-F2 62-70 and NP 366-374 demonstrate kinetic behavior completely consistent with rapid degradation unless bound to MHC class I molecules, whereas PA 224-233 demonstrates kinetics not previously observed (for either proteins or minigene products) that are consistent with it forming a substantial pool that forms a steady source of peptides for hours after shutting off its biosynthetic source.
PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] Peptide Cellular Pool Is Dependent on Cellular HSP90 Activity The recent report from Kunisawa and Shastri (2006) demonstrating that HSP90a associates with proteolytic fragments of KOVAK, a misfolded cytosolic model antigen, prompted us to examine the effect of cell-permeant small molecule inhibitors of HSP90. These inhibitors are among the most selective inhibitors available to probe intracellular pathways. All of the inhibitors used target the NH 2 -terminal ATP binding domain of HSP90 family members. Two of the inhibitors used, 17AAG and 17DMAG, are second generation geldanamycin analogs with higher potency than the parent, while the third, radicicol, is chemically distinct from geldanamycin, and so would be expected to have a distinct off-target profile. Cells were treated with the given HSP90 inhibitor at 30 min after infection to allow viral penetration to occur and to minimize effects on viral gene expression ( Figure 3 ). Treatment with each of the inhibitors inhibited D b -PA 224-233 cell-surface complex expression by approximately 20%-30%. This is not specific for PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] , as shown by the fact that NP 366-374 and PB1-F2 62-70 decreased similarly (data not shown) and probably reflects a requirement for active HSP90 for maximal VV gene expression.
To assess the effect of HSP90 inhibitors on PA 224-233 pool formation in this experiment, we incubated the cell with protein synthesis inhibitors at 240 min ( Figures 3E-3G ). This revealed that each of the HSP90 inhibitors tested eliminated the PA 224-233 peptide pool. Importantly, addition of HSP90 inhibitors simultaneously with PSI failed to diminish complex expression (Figure 3G) , indicating that maintenance of the peptide pool does not require active HSP90.
The Hsp90 family consists of cytosolic Hsp90a, Hsp90b, the ER paralog GRP94, and mitochondrial Trap-1, all of which are sensitive to the panel of HSP90 inhibitors. To identify the relevant targets involved in PA 224-233 peptide pool formation, we transfected L-D b cells with siRNAs specific for HSP90 (a&b) (the siRNA sequences do not distinguish between these highly similar genes), GRP94, or Neomycin (negative control). Cells were retransfected 4 days after the initial transfection and used 4 days later. This resulted in a greater than 10-fold specific reduction in HSP90 and GRP94 as determined by immunoblotting of total cell lysates ( Figure 4A ). These cells were infected with the rVV expressing ER-targeted PA 224-233 and tested for PA 224-233 pool formation as described above by the effect of protein synthesis inhibition on continued complex expression (Figures 4B and 4C) . This revealed that mock transfected cells or cells transfected with control siRNA or with GRP94 siRNA exhibited a large PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] pool that remained completely sensitive to HSP90 inhibition by 17AAG. By contrast, the pool was nearly completely depleted by HSP90 (a&b) knockdown.
These data demonstrate that the PA 224-233 pool is formed independently of GRP94 but requires functional cytosolic HSP90.
PA 224-233 Physically Associates with a HSP90 Inhibitor-Sensitive Receptor in Living Cells
These findings were consistent with the idea that PA 224-233 physically associates with HSP90 or a HSP90-sensitive client. To investigate the possible interaction of PA 224-233 with a cytosolic receptor, we microinjected L-D b cells with synthetic PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] or PB1-F2 62-70 (as a control) with a COOH-terminal Lys residue conjugated with fluorescein at its 3-NH 2 -group (PA 224-233KFl, ). Each peptide distributed evenly between cytosolic and nuclear compartments ( Figures 5A and 5B ). This contrasts with the findings of Reits et al. (2003) that microinjected peptides typically concentrate in the nucleus because of their protection from proteolysis by chromatin. In other experiments (unpublished observations), we observed that another microinjected peptide with Lys-fluorescein (SIINFEK FL L) demonstrates nuclear localization. It is likely that these differences reflect chemical differences in the peptides used in these disparate studies that govern their interaction with cellular constituents. We measured the mobility of cytosolic PA 224-233KFl by fluorescence recovery after photobleaching (FRAP) analysis and compared its properties to PB1-F2 62-70KFl as a control ( Figure 5C ). PA 224-233KFl demonstrated a substantially slower diffusion coefficient than did PB1-F2 62-70KFl . Critically, treating cells with 17AAG for 20 min prior to microinjection did not affect the diffusion coefficient of PB1-F2 62-70KFL but did increase the diffusion coefficient of PA to match that of PB1-F2 62-70KFL . It was of interest to compare the mobility peptides to full-length proteins. Consistent with Reits et al. (2003) , the mobility of PB1-F2 62-70KFl was $20% greater than that of GFP, which in turn was substantially more mobile than a HSP90a-GFP cherry construct ( Figure 5 ). Importantly, although GFP mobility was unaffected by 17AAG, HSP90a-GFP cherry demonstrated a substantial increase in mobility (though less mobile than GFP, as expected from its larger radius of gyration), providing the initial FRAP evidence for the physical interaction of a HSP90 family member peptide binding site. This contrasts with HSP90b, whose mobility is reported to be insensitive to HSP-90 inhibitors (Picard et al., 2006) . These data demonstrate that 17AAG detectably affects HSP90 mobility in living cells and are consistent with the conclusion that PA 224-233 associates with a cytosolic partner that requires HSP90 peptide binding activity: either HSP90 itself, or a client that is rather rapidly altered by HSP90 inhibition. Figure 6B ). (Note that it is likely that substantial amounts of ER-targeted peptides persist in the cytosol, resulting either from inefficient targeting of such small proteins to the ER or from the recycling of excess peptides from the ER to the cytosol [Koopmann et al., 2000; Roelse et al., 1994] ). The TAP independence of cytosolic PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] crosspriming is in agreement with the finding that cytosolic HSP90 but not GRP94 is involved in peptide pool formation (Figure 4 ). We more directly tested the involvement of functional HSP90 in PA 224-233 crosspriming by treating donor cells with 17AAG during rVV infection prior to their introduction into B6 mice (Figure 6C ). This reduced PEC and splenic anti-PA 224-233 responses by $85% while reducing B8R 20-27 or overall VV-specific response by 15% to 50%.
Next, we examined the requirement for GRP94 in crosspriming by using human HEK293 cells stably transfected with GRP94-targeting siRNA (control HEK293 cells were stably transfected with the same sequence but scrambled). Via immunoblotting, GRP94 is undetectable in knockdown cells whereas HSP90 amounts are similar between control and knockdown cells (Figure 6D) . Despite the absence of GRP94, both rVVs expressing cytosolic and ER-targeted PA 224-233 were effective at crosspriming for PA 224-233 -specific, B8R 20-27 -specific, and total VVspecific CD8 + T cell responses ( Figures 6E and 6F ). Figure 7A ). Antigenic activity in peak fractions could be detected at a dilution of 1/12,500, whereas activity in infected L929 cells titrated at least 1000-fold lower amounts. This is consistent with the classically reported rapid degradation of peptides lacking a high-affinity class I receptor. All of our evidence points to the conclusion that the PA 224-233 pool is present in the cytosol. We consider it extremely unlikely that the pool is present as a complex with a class Ia or Ib molecule expressed by L929 cells (particularly because the pool also exists in T2 cells, which, in addition to lacking TAP, express a completely different set of class I molecules becuase they are of human origin). Based on the unprecedented nature of the pool, however, we thought it prudent to perform an additional experiment to characterize the possible contribution of class I protected peptides to crosspriming in the VV system we employ.
To 
DISCUSSION
Proteasomal protein cleavage generates oligopeptides of between 3 and 32 residues that are degraded by highly active cytosolic endopeptidases and aminopeptidases (Kisselev et al., 1998; Reits et al., 2004) . The half-life of oligopeptides in this aggressively degradative environment is believed to be $10 s. Inasmuch as proteasome-generated peptides are functionless, potentially dangerous agents that can interfere with cellular functions (including impeding the interaction of molecular chaperones with their substrates), the rapid removal of peptides and reutilization of amino acids is logical. Despite this, a considerable literature has accrued regarding the potential role of GRP94 and other abundant molecular chaperones in protecting peptides from degradation and promoting peptide immunogenicity upon transfer to pAPCs. There is compelling evidence that molecular chaperones have a bona fide role in activating innate immune receptors (Baker-LePain et al., 2002; Oizumi et al., 2007) . The function of molecular chaperones, however, in specifically binding and delivering oligopeptides generated from biosynthesized proteins to pAPCs is controversial. Molecular chaperones exhibit low affinity for their substrates (on the order of 0.1 mM), consistent with their need to transiently interact with clients to promote folding (Flynn et al., 1989 (Flynn et al., , 1991 Fourie et al., 1994; Ying and Flatmark, 2006) . With such a low affinity, peptides would be protected only fleetingly, achieve low steady-state amounts in living cells, and dissociate rapidly upon release from cells and delivery to pAPCs. Although there is limited evidence for recovery of defined peptides from GRP94 purified from cells, others have found only minute quantities of peptides bound to GRP94 and have questioned the peptide-chaperoning function of GRP94 in antigen presentation (Demine and Walden, 2005; Nicchitta et al., 2004; Wallin et al., 2002; Ying and Flatmark, 2006) . Moreover, molecular chaperones are only weakly immunogenic relative to cell-associated immunogens, even when loaded in vitro to the maximal extent attainable with synthetic peptides. Even non-cell-associated heat-aggregated viruses or proteins are more immunogenic than the most potent HSP preparations reported (Cho et al., 2003; Speidel et al., 1997) .
On top of this, we and others have provided evidence strongly supporting a central role for intact proteins in crosspriming (Basta et 2004; Wolkers et al., 2004) . Cellular oligopeptides generated via signal peptidase liberation or synthesized as cytosolic or ER-targeted minigene products display little to no crosspriming activity (Gasteiger et al., 2007; Norbury et al., 2004; Serna et al., 2003) .
The poor crosspriming capacity of minigene products, consistent with the lack of crosspresentation of minigene products observed in vitro by Serna et al. (2003) , can be explained by their rapid degradation. Like naturally processed antigenic peptides, recovery of minigene-encoded minimal peptides from cells is heavily dependent on the presence of a high-affinity class I receptor (Anton et al., 1997) . More recently, we precisely quantitated cell-surface K b -Ova 257-264 complex expression in cells infected with VV-Ova 257-264 by using the TCR-like mAb 25-D1.16 (Princiotta et al., 2003) . Upon abrogation of protein synthesis, delivery of K b -Ova 257-264 complexes to the cell surface ceased rapidly, consistent with the rapid degradation of Ova [257] [258] [259] [260] [261] [262] [263] [264] .
In the present study, we extend these findings to three additional defined peptides expressed as cytosolic or ER-targeted minigenes. By using a novel panel of TCR-like Abs to measure cell-surface D b -peptide complex expression, we found that for two of the peptides, NP [366] [367] [368] [369] [370] [371] [372] [373] [374] , the kinetics of shutdown of complex delivery to the cell surface after inhibiting protein synthesis was virtually identical to those observed after BFA blockade of D b -peptide complex egress from the early secretory pathway, providing unequivocal evidence for the absence of a protected peptide pool capable of supplying the class I pathway. Crucially, these peptides also failed to exhibit substantial crosspriming activity when expressed in cells lacking D b . In distinct contrast, whereas BFA rapidly abrogated cellsurface delivery of PA 224-233 complexes, delivery continued for hours after abrogation of protein synthesis, indicative of a sizable intracellular pool. This pool is independent of D b expression, as demonstrated by the crosspriming activity of PA 224-233 minigene products in L929 cells and also the recovery of large amounts of PA 224-233 via acid extraction from the same cells. The TAP independence of PA 224-233 minigene product crosspriming points to a cytosolic location for the PA 224-233 pool. Consistent with this interpretation, the PA 224-233 pool and its crosspriming activity is abrogated by selectively interfering with cytosolic HSP90 function or expression and is unaffected by ER GRP94 knockdown. Further, we show that upon microinjection, a fluorescent derivative of PA 224-233 diffuses more slowly in the cytosol than an equivalent form of PB1-F2 62-70 , an effect that is rapidly abrogated by addition of a HSP90 inhibitor. This is consistent with the binding of PA 224-233 to a HSP90-dependent cytosolic partner that retards its diffusion. We were unable to recover PA 224-233 with HSP90-specific antibodies to purify HSP90 from cytosol recovered from semi-intact cells or TX100 lysates (data not shown). Kunisawa and Shastri (2006) recovered numerous fragments of KOVAK from HSP90 antibody pulldowns. It is uncertain, however, whether these peptides directly associate with HSP90, because HSP90 participates in large complexes containing other client-binding molecular chaperones. Two findings favor the idea that PA 224-233 is only indirectly influenced by HSP90 activity. First, the PA 224-233 pool persists for hours after protein synthesis inhibition, suggesting a high-affinity interaction with its chaperone. Second, adding HSP90 inhibitors at the time of protein synthesis blockade did not deplete the pre-existing PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] pool. This strongly sug- gests that pool formation is not directly based on association of PA 224-233 with HSP90, because HSP90 inhibitors would be predicted to cause either the release of PA 224-233 from HSP90 and rapid proteolysis or the Ub-dependent degradation of HSP90-bound PA 224-233 (Isaacs et al., 2003) . In support of the rapid action of HSP90 inhibitors, we show that 17AAG rapidly increases the diffusion of HSP90a in living cells.
Notably, inactivation or depletion of HSP90 and GRP94 had little effect on the crosspriming capacity of B8R 20-27 -specific CD8 + T cells or polyclonal anti-VV CD8 + T cell responses. It is possible that other molecular chaperones are involved in crosspriming for these natural gene products. We believe it is unlikely, however, that this involves chaperoned peptides generated from these proteins. Our findings demonstrate that oligopeptides are capable of crosspriming if they are spared from proteolysis. Thus, the inability of other minigene products or efficiently liberated peptides (such as signal sequences or oligopeptides released from Ubfusion proteins by Ub-hydrolases) to crossprime can be directly attributed to their evanescence and not the general inability of oligopeptides to survive transfer to, and further processing in, pAPCs. This strongly implies that the poor immunogenicity of rapidly degraded model proteins, and presumably natural DRiPs as well, can be attributed to the rapid degradation of most proteasomal products, which simply do not achieve the steadystate quantities needed for crosspriming. On the other hand, our finding that a subset of peptides is resistant to rapid proteolysis would favor the possible contribution of CD8 + T cell priming via oligopeptide transfer to pAPCs through gap junctions, which has been elegantly shown to function cultured cells by Neefjes and colleagues (Neijssen et al., 2005 (Neijssen et al., , 2007 .
EXPERIMENTAL PROCEDURES Mice
All experiments used 6-to 10-week-old female C57BL/6J mice purchased from Taconic Farms. Mice were housed in the animal care facility at National Institute of Allergy and Infectious Diseases (NIAID) under specific pathogenfree conditions and maintained on standard mouse chow and water provided ad libitum. The NIAID Animal Care and Use Committee approved all animal procedures and studies.
Peptides, MHC Complexes, and Reagents
Peptides were procured and characterized by the Biologic Resource Branch, NIAID (Rockville, MD). In each case, substances with the predicted mass constituted >95% of the material analyzed. Peptides were dissolved in DMSO at 10 mM and stored at À20 C. FITC-labeled peptides (LSLRNPILV[K-3-fluorescein]-OH, PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] , or SSLENFRAYV[K-3-fluorescein]-OH, PB1-F2 62-70 ) were dissolved in DMSO at a concentration of 10 mg/ml and kept in À20 C until use.
Immediately before microinjection, stock peptide solution was diluted to 100 ng/ml in Dulbecco's P with calcium and magnesium (DPBS). Biotinylated MHC monomers were provided by the NIAID tetramer facility (Emory University, Atlanta, GA). Cbz-Leu-Leu-Leucinal (zLLL), lactacystin were from Sigma (St. Louis, MO). Abs to hsp90 (rat IgM Ab 1R2D12p90) and grp94 (rat IgG2a Ab 9G10) were from StressGen (Victoria, British Columbia, Canada). (these sequences have been picked from Dharmacon on target sequences) used in a mixture of 10 nM each. siRNA specific for GRP94 and Neo were 5 0 -pGGCUCAAGGACAGAUGAUGtt and pAAUGAACUGCAGGACGAGGCAtt used at 10 nM each. All siRNAs were purchased from Dharmacon (Lafayette, CO). For maximal knockdown, transfection was repeated after 4 days and cells were harvested for experiments 4 days after the second transfection. Knockdown effectiveness was determined by immunoblotting with GRP94-and HSP90-specific antibodies.
rVV Infections rVVs containing minigenes encoding PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] , and PB1-F2 62-70 peptides in the cytosol or targeted to the ER were generated as described for other minigene-expressing rVVs (Anton et al., 1997) Cells were infected at a multiplicity of infection (MOI) of 10 for 20 min at 37 C with mixing every few minutes in balanced salt solution containing 0.1% bovine serum albumin (BSS/BSA). Cells were then incubated at 37 C in growth media for the remainder of the assay in the presence of 25 mg/ml cytosine arabinoside (Sigma, St. Louis, MO). Protein synthesis was inhibited by the addition of cycloheximide and emetine (Sigma, St. Louis, MO) to a final concentration of 25 mg/ml each. Brefeldin A (BFA) (Sigma, St. Louis, MO) was added to a final concentration of 10 mg /ml.
Phage Ab Generation
Selection of phage antibodies on biotinylated MHC complexes was preformed, as described (Lev et al., 2002) . In brief, a large human Fab library containing 4 3 10 10 different Fab clones was used for the selection with decreasing amounts of biotinylated MHC-peptide complexes (25 mg for the first round and 5 mg for the following rounds). Streptavidin-coated magnetic beads (200 ml for the first round of selection and 100 ml for the following rounds) were incubated with Phage mixture for 15 min at RT. The beads were washed extensively 12 times with PBS/0.1% Tween + 2% milk and additional two washes with PBS. Bound phages were then eluted with triethylamine (100 mM, 5 min at RT) followed by neutralization with Tris-HCl (1 M, pH 7.4) and used to infect E. coli TG1 cells (at OD 600 = 0.5) for 30 min at 37 C. The diversity of the selected antibodies was determined by DNA fingerprinting with a restriction endonuclease (BstNI), which is a frequent cutter of antibody V gene sequences. The Fab DNA of different clones was PCR amplified with the primers pUC-reverse (5 0 -AGCGGATAACAATTTCACACAGG-3 0 ) and fd-tet-seq (5 0 -TT TGTCGTCTTTCCAGACGTTAGT-3 0 ), followed by digestion with BstNI (NEB, Beverly, MA) (2 hr, 60 C) and analysis on agarose gel electrophoresis (data not shown).
Expression and Purification of Soluble Recombinant Fab Abs
Fab antibodies were expressed and purified as described (Lev et al., 2002) . 
Microscopy and FRAP Analysis
Cells were examined and manipulated with a Leica TCS-SP5 DMI6000 with 8000 Hz resonant scanner and 403 1.25 NA oil objective (Leica Microsystems, Germany). The microscope was equipped with a Cube & the Box environmental chamber (Life Imaging Services, Switzerland). Cells were maintained at 37 C in 95%/5% air/CO 2 mixture. Peptides were microinjected into cells with an Eppendorf FemtoJet microinjector system (Eppendorf, NY). Cells were also transfected with eGFP or mCherry-HSP90a plasmids as controls with Amaxa nucleofactor with T-24 program. Prior to FRAP, a rectangular 9 mm 3 35 mm area was positioned on a microinjected cell with a bleaching area of 6 mm 3 13 mm size placed in the center of the cells. 20 frames in 0.01 s were collected before bleaching was performed for 0.2 s at the maximum laser power of 458, 476, and 488 nm laser lines. Fluorescence recovery was monitored at a collection rate of 100 frames per 0.01 s. At least 50 cells for each condition were measured in more than three independent experiments. FRAP recovery half-times were calculated with Leica Application Suite Advanced Fluorescence software.
Extracting Antigenic Peptides from rVV Minigene-Infected Cells, HPLC Run, and Measure of CTL Responses 5 3 10 8 L929 and 1.25 3 10 8 L-D b cells were infected with rVV-NP 366-372 or rVV-PA 224-233 at 20 pfu:cell. Cells were harvested 3 hr after infection, snap frozen, and resuspended in 8 ml 0.1% TFA/H 2 O. After adding 3 ml of 1% TFA/ H 2 O, cells were disrupted by >20 strokes in a Dounce homogenizer, sonicated, and rotated on wheel for 30 min at 4 C. The lysate was pelleted by low-speed centrifugation, and the supernatant was passed through a 0.45 mM syringe filter and then a 3K cut-off filter (Macrosep, filtron 3K, Cat OD003C36, Pall Filtron Corp., Northborough, MA). The filtrate was speed dried with vacuum to a volume of less then 400 ml. The sample was filtered through a 0.45 mM microfilter that was previously washed with 0.1% TFA solution before use and then directly loaded onto a HPLC C-18 column (Deltapack, Waters). Fractions were collected every tenth of a minute from 10 min after injection until 38.8 min (3 3 96-well plates) and stored at 4 C. ICS was performed as described for crosspriming experiments with HPLC fractions to stimulate CD8 + T cell lines propagated in vitro by stimulation with NP 366-374 or PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] .
Crosspriming Experiments with Intracellular Cytokine Staining L929 or HEK293 cells were infected at 10 MOI with rVVs expressing the IAVderived peptides as minigenes for 6 hr before UV irradiation. After washing, 10 million cells were injected i.p. into each B6 mouse. Six days later, splenic and peritoneal L929 cells from primed animals were suspended in RPMI 1640 medium plus 10% FBS and 10 mM HEPES buffer and seeded at 2 3 10 6 cells/well in U-bottom, 96-well plates. Peptides were added to wells to a final concentration of 0.5 mM. Cells were incubated initially for 1-2 hr at 37 C and then for 3 hr with brefeldin A (BFA; Sigma-Aldrich, St. Louis, MO) at 10 mg/ml. Cells were then stained with CyChrome anti-CD8a mAb on ice for 30 min, washed, and fixed with 1% paraformaldehyde in PBS at room temperature for 20 min, then further stained with FITC-conjugated anti-IFN-g in PBS containing 0.1% saponin (Sigma-Aldrich). Stained cells were analyzed on a FACSCalibur (BD Biosciences, Sunnyvale, CA) with live-gate on the CD8 + cells. A total of 150,000 cells were normally acquired and analyzed with FlowJo software (TreeStar, Ashland, OR).
SUPPLEMENTAL DATA
Two figures are available at http://www.immunity.com/cgi/content/full/28/6/ 787/DC1/.
